Oncologic outcomes for lymph node-positive urothelial carcinoma patients treated with robot assisted radical cystectomy: With mean follow-up of 3.5 years
Oncologic outcomes for lymph node-positive urothelial carcinoma patients treated with robot assisted radical cystectomy: With mean follow-up of 3.5 years
复制标题
DOI：
10.1016/j.urolonc.2012.03.001
复制
发表时间：
2013-11-01
影响因子：
2.7
通讯作者：
Castle, Erik P.
中科院分区：
文献类型：
--
作者：
Mmeje, Chinedu O.;Nunez-Nateras, Rafael;Castle, Erik P.
目的：既往研究表明，机器人辅助根治性膀胱切除术（RARC）与开放根治性膀胱切除术具有可比的围手术期结局。很少有报告研究了RARC的肿瘤学结果，特别是关于淋巴结阳性患者。我们报告的病理淋巴结阳性患者谁经历了RARC中期following.Materials和方法的结果：共275例患者在2个机构进行RARC浸润性膀胱癌2005年4月至2009年6月。我们检查了50例淋巴结阳性疾病患者。肿瘤的结果，总体，和无复发生存进行了分析，并与开放literature.Results比较：平均（中位数）在这个队列的临床随访时间为42（39.5）个月（范围16-75个月）。切除的淋巴结（LN）平均（中位数）数量为18（17.5）（范围5-35），阳性LN平均（中位数）数量为3（2）（范围1-12）。平均淋巴结密度为18%。17例（34%）患者
Purpose: Previous studies have shown robot assisted radical cystectomy (RARC) to have comparable perioperative outcomes to open radical cystectomy. There are few reports that have examined the oncologic results of RARC, specifically with respect to lymph node-positive patients. We report the outcomes of pathologic node-positive patients who have undergone RARC with medium-term follow-up.Materials and methods: A total of 275 patients underwent RARC at 2 institutions for invasive bladder cancer between April 2005 and June 2009. We examined the 50 patients with lymph node-positive disease. Oncologic outcomes, overall, and recurrence-free survival were analyzed and compared with the open literature.Results: Mean (median) clinical follow-up in this cohort was 42 (39.5) months (range 16-75 months). The mean (median) number of lymph nodes (LN) removed was 18 (17.5) (range 5-35), and mean (median) number of positive LN was 3 (2) (range 1-12). Mean lymph node density was 18%. Seventeen (34%) patients had